DexCom, Inc. reiterated earnings guidance for the fiscal year 2022. For the year, the company expects revenue of approximately $2.82 - $2.94 billion, representing growth of 15% to 20%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
128.1 USD | +0.57% | +1.18% | +3.26% |
Apr. 30 | Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology | CI |
Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.26% | 50.67B | |
-4.91% | 183B | |
+0.46% | 108B | |
-3.62% | 67.51B | |
+9.11% | 44.7B | |
+3.57% | 40.95B | |
+6.39% | 26.8B | |
+3.83% | 26.71B | |
+14.93% | 24.62B | |
-13.28% | 21.38B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022